Last reviewed · How we verify
IBP-9414
IBP-9414 is a live biotherapeutic product designed to restore beneficial bacterial populations in the infant microbiome.
IBP-9414 is a live biotherapeutic product designed to restore beneficial bacterial populations in the infant microbiome. Used for Microbiome restoration in infants (specific indication under investigation in Phase 3).
At a glance
| Generic name | IBP-9414 |
|---|---|
| Sponsor | Infant Bacterial Therapeutics |
| Drug class | Live biotherapeutic product |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease / Pediatrics |
| Phase | Phase 3 |
Mechanism of action
IBP-9414 is a rationally selected consortium of commensal bacteria intended to establish or restore healthy microbial communities in infants. By introducing specific bacterial strains, the therapeutic aims to promote normal microbiome development and prevent dysbiosis-related complications. This approach leverages the critical role of early-life microbiota in immune system development and disease prevention.
Approved indications
- Microbiome restoration in infants (specific indication under investigation in Phase 3)
Common side effects
Key clinical trials
- IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study (PHASE3)
- IBP-9414 for the Prevention of Necrotizing Enterocolitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |